• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Paramount Global Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

    7/8/24 5:40:41 AM ET
    $AZ
    $BENF
    $CLEU
    $DYNT
    Industrial Machinery/Components
    Industrials
    Finance: Consumer Services
    Finance
    Get the next $AZ alert in real time by email

    Shares of Paramount Global (NASDAQ:PARAA) rose sharply in today's pre-market trading.

    Paramount Global and Skydance Media inked a definitive agreement to create a new entity, "New Paramount," in a $28 billion merger deal.

    Paramount Global shares jumped 7.5% to $22.00 in pre-market trading.

    Here are some other stocks moving in pre-market trading.

    Gainers

    • Shapeways Holdings, Inc. (NASDAQ:SHPW) rose 93.7% to $0.4068 in pre-market trading after dipping 22% on Friday.
    • Inspire Veterinary Partners, Inc. (NASDAQ:IVP) shares rose 52.3% to $2.27 in pre-market trading after gaining 8% on Friday.
    • Dynatronics Corporation (NASDAQ:DYNT) shares rose 36.6% to $0.29 in pre-market trading after declining around 8% on Friday.
    • Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) gained 27% to $5.17 in pre-market trading after jumping around 50% on Friday.
    • Maxeon Solar Technologies, Ltd. (NASDAQ:MAXN) shares rose 24.8% to $0.2997 in pre-market trading after jumping over 38% on Friday.
    • Grifols, S.A. (NASDAQ:GRFS) rose 22.9% to $8.65 in pre-market trading. Grifols shares gained around 6% on Friday after the company appointed Rahul Srinivasan as CFO, effective Sept. 16.
    • IDEAYA Biosciences, Inc. (NASDAQ:IDYA) shares gained 17.8% to $40.37 in pre-market trading. IDEAYA will present clinical data update for IDE397 Phase 2 monotherapy expansion dose in MTAP-deletion urothelial and lung cancer on July 8, 2024.
    • R1 RCM Inc. (NASDAQ:RCM) shares climbed 13.2% to $12.39 in pre-market trading.
    • NANO Nuclear Energy Inc. (NASDAQ:NNE) shares gained 10.9% to $31.50 in pre-market trading after surging 20% on Friday.

    Losers

    • China Liberal Education Holdings Limited (NASDAQ:CLEU) shares fell 21.6% to $1.71 in pre-market trading after dipping 24% on Friday.
    • Beneficient (NASDAQ:BENF) shares fell 15.1% to $4.11 in pre-market trading. Beneficient said it will release its fourth quarter financial results before the opening bell on Tuesday, July 9.
    • Qualigen Therapeutics, Inc. (NASDAQ:QLGN) shares declined 14.1% to $0.2408 in pre-market trading after jumping 60% on Friday.
    • Inventiva S.A. (NYSE:IVA) shares fell 13.8% to $2.55 in pre-market trading after the company issued an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position.
    • Assure Holdings Corp. (NASDAQ:IONM) fell 13.3% to $0.2740 in pre-market trading.
    • Adamas One Corp (NASDAQ:JEWL) shares dipped 12.3% to $0.32 in pre-market trading after dipping over 20% on Friday.
    • Vivakor inc (NASDAQ:VIVK) shares fell 11.6% to $2.05 in pre-market trading.
    • A2Z Smart Technologies Corp (NASDAQ:AZ) shares declined 11.5% to $0.38 in pre-market trading after gaining around 11% on Friday.
    • ZIM Integrated Shipping Services Ltd. (NYSE:ZIM) shares fell 6.4% to $20.70 in pre-market trading.
    • Stitch Fix, Inc. (NASDAQ:SFIX) fell 5.3% to $3.95 in pre-market trading after gaining over 7% on Friday

    Now Read This: Top 3 Financial Stocks You’ll Regret Missing In Q3

    Get the next $AZ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZ
    $BENF
    $CLEU
    $DYNT

    CompanyDatePrice TargetRatingAnalyst
    A2Z Cust2Mate Solutions Corp.
    $AZ
    3/27/2026$15.00Outperform
    Northland Capital
    Inventiva S.A.
    $IVA
    3/19/2026$13.00Buy
    Truist
    Inventiva S.A.
    $IVA
    1/28/2026$18.00Overweight
    Barclays
    Inventiva S.A.
    $IVA
    1/12/2026$12.00Outperform
    Leerink Partners
    IDEAYA Biosciences Inc.
    $IDYA
    1/7/2026$50.00Buy
    UBS
    Inventiva S.A.
    $IVA
    1/7/2026$12.00Buy
    UBS
    IDEAYA Biosciences Inc.
    $IDYA
    11/24/2025Buy
    Truist
    Inventiva S.A.
    $IVA
    11/6/2025$13.00Outperform
    Wolfe Research
    More analyst ratings

    $AZ
    $BENF
    $CLEU
    $DYNT
    SEC Filings

    View All

    SEC Form 6-K filed by ZIM Integrated Shipping Services Ltd.

    6-K - ZIM Integrated Shipping Services Ltd. (0001654126) (Filer)

    4/23/26 4:05:03 PM ET
    $ZIM
    Marine Transportation
    Consumer Discretionary

    SEC Form 6-K filed by Inventiva S.A.

    6-K - Inventiva S.A. (0001756594) (Filer)

    4/22/26 4:23:18 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 6-K/A filed by ZIM Integrated Shipping Services Ltd.

    6-K/A - ZIM Integrated Shipping Services Ltd. (0001654126) (Filer)

    4/22/26 4:05:16 PM ET
    $ZIM
    Marine Transportation
    Consumer Discretionary

    $AZ
    $BENF
    $CLEU
    $DYNT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stein Jeffrey bought $1,647,890 worth of shares (50,000 units at $32.96), increasing direct ownership by 1,168% to 54,281 units (SEC Form 4)

    4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)

    3/2/26 7:18:09 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Cangany Peter T Jr bought $23,750 worth of shares (25,000 units at $0.95) (SEC Form 4)

    4 - Beneficient (0001775734) (Issuer)

    11/25/24 4:29:26 PM ET
    $BENF
    Finance: Consumer Services
    Finance

    Director Cangany Peter T Jr bought $69,500 worth of shares (75,000 units at $0.93) (SEC Form 4)

    4 - Beneficient (0001775734) (Issuer)

    11/20/24 6:03:20 AM ET
    $BENF
    Finance: Consumer Services
    Finance

    $AZ
    $BENF
    $CLEU
    $DYNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Hicks Mack H.

    3 - Beneficient (0001775734) (Issuer)

    4/20/26 7:01:44 PM ET
    $BENF
    Finance: Consumer Services
    Finance

    SEC Form 4 filed by O'Connor Casey

    4 - Stitch Fix, Inc. (0001576942) (Issuer)

    4/13/26 4:10:01 PM ET
    $SFIX
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form 3 filed by new insider Wang Cheng Kevin

    3 - Maxeon Solar Technologies, Ltd. (0001796898) (Issuer)

    4/13/26 6:04:27 AM ET
    $MAXN
    Semiconductors
    Technology

    $AZ
    $BENF
    $CLEU
    $DYNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Northland Capital initiated coverage on A2Z Cust2Mate Solutions Corp. with a new price target

    Northland Capital initiated coverage of A2Z Cust2Mate Solutions Corp. with a rating of Outperform and set a new price target of $15.00

    3/27/26 8:45:14 AM ET
    $AZ
    Industrial Machinery/Components
    Industrials

    Truist initiated coverage on Inventiva with a new price target

    Truist initiated coverage of Inventiva with a rating of Buy and set a new price target of $13.00

    3/19/26 8:26:25 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Inventiva with a new price target

    Barclays initiated coverage of Inventiva with a rating of Overweight and set a new price target of $18.00

    1/28/26 7:17:30 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZ
    $BENF
    $CLEU
    $DYNT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma

    SOUTH SAN FRANCISCO, Calif., April 21, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, today announced they have been selected for a late-breaking abstract (LBA) oral presentation to provide the complete data from the Phase 2/3 registrational trial (OptimUM-02) of darovasertib in combination with crizotinib in first-line (1L) HLA*A2-negative metastatic uveal melanoma at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on May 29-June 2 in Chicago, Illinois. The presentation will include detail and additional data from OptimUM-02 that were not disclosed with the company's topline release.

    4/21/26 10:15:00 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NANO Nuclear Announces Platinum Sponsorship and Executive Participation at the Upcoming Reuters Events' SMR & Advanced Reactor 2026 Conference

    New York, N.Y., April 21, 2026 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ:NNE) ("NANO Nuclear" or "the Company"), a leading advanced nuclear micro modular reactor (MMR) and technology company focused on developing clean energy solutions, today announced its Platinum Sponsorship of SMR & Advanced Reactor 2026 Conference, hosted by Reuters Events on May 11-12, 2026, in Austin, Texas. Reuters Events' SMR & Advanced Reactor 2026 is the worldwide hub for new nuclear, uniting more than 750 leaders from utilities, tech, finance, and regulators to shape game-changing partnerships, plan smarter, and position nuclear as the scalable solution for energy security. On May 11, 2026, James Wa

    4/21/26 8:30:00 AM ET
    $NNE
    Electric Utilities: Central
    Utilities

    NANO Nuclear Announces Platinum Sponsorship and Executive Participation at the Upcoming Reuters Events' SMR & Advanced Reactor 2026 Conference

    New York, New York--(Newsfile Corp. - April 21, 2026) - NANO Nuclear Energy Inc. (NASDAQ:NNE) ("NANO Nuclear" or "the Company"), a leading advanced nuclear micro modular reactor (MMR) and technology company focused on developing clean energy solutions, today announced its Platinum Sponsorship of SMR & Advanced Reactor 2026 Conference, hosted by Reuters Events on May 11-12, 2026, in Austin, Texas.Reuters Events' SMR & Advanced Reactor 2026 is the worldwide hub for new nuclear, uniting more than 750 leaders from utilities, tech, finance, and regulators to shape game-changing partnerships, plan smarter, and position nuclear as the scalable solution for energy security. On May 11, 2026, James Wa

    4/21/26 7:59:00 AM ET
    $NNE
    Electric Utilities: Central
    Utilities

    $AZ
    $BENF
    $CLEU
    $DYNT
    Leadership Updates

    Live Leadership Updates

    View All

    ZIM Updates on Withholding Tax Procedures on March 2026 Cash Dividend

    HAIFA, Israel, March 19, 2026 /PRNewswire/ -- ZIM Integrated Shipping Services Ltd. (NYSE:ZIM) ("ZIM" or the "Company"), a global container liner shipping company, hereby updates that in connection with the dividend distribution expected to take place on March 26, 2026, as previously announced by the Company on March 9, 2026 (the "Dividend"), the previously obtained tax ruling from the Israeli Tax Authority ("ITA") on tax withholding procedures relating to the payment of the Dividend to the Company's shareholders (the "Ruling"), as extended, shall apply.   As a result of the Ruling, certain shareholders of the Company ("Shareholders") may be eligible to a reduced Israeli withholding tax rate

    3/19/26 7:00:00 AM ET
    $ZIM
    Marine Transportation
    Consumer Discretionary

    Beneficient Appoints Mack H. Hicks to Board of Directors

    DALLAS, March 12, 2026 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ:BENF), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets, today announced the appointment of Mack H. Hicks as a member of the Company's Board of Directors (the "Board"). Mr. Hicks currently serves as Chief Executive Officer of Hicks Holdings LLC, the Dallas-based family office with operating private equity and real estate investment businesses founded by his late father and private equity pioneer, Thomas O. Hicks, who served as Chairman of the Board of Beneficient until his passing in December of 2025. Mr. Hicks also

    3/12/26 7:30:00 AM ET
    $BENF
    Finance: Consumer Services
    Finance

    IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer

    SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, today announced the appointment of Dr. Theodora (Theo) Ross into the newly created role of Chief Development Officer. In this role, Dr. Ross will be responsible for leading early clinical development for IDEAYA's emerging oncology pipeline and play a crucial role in guiding the company's long-term R&D strategy. Dr. Ross joins IDEAYA from AbbVie, where she served as Vice President, Head of Early Oncology R&D and Site Head for the Bay Area. 

    2/23/26 6:00:00 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZ
    $BENF
    $CLEU
    $DYNT
    Financials

    Live finance-specific insights

    View All

    A2Z Cust2Mate Announces Business Updates and Investor Conference Call

    TORONTO, April 15, 2026 /CNW/ - A2Z Cust2Mate Solutions Corp. (NASDAQ:AZ), a global leader in smart retail technology, today announces a series of significant business updates reflecting continued commercial momentum, global expansion, and financial progress: Record Smart Cart Orders Surpass $175 Million, Driving Global Deployment MomentumThe Company reported a record scale of smart cart purchase orders valued at over $175 million1 (over the lifetime of the contract, excluding Retail Media revenues), representing deployments of more than 17,000 smart carts across leading retailers. These include Carrefour Israel, Yochananof, Sapir Group, Toys "R" Us Israel, The Red Pirate, and a leading reta

    4/15/26 7:00:00 AM ET
    $AZ
    Industrial Machinery/Components
    Industrials

    IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma

    Trial met the primary endpoint showing statistically significant improvement in median PFS by BICR, with 6.9 months for the darovasertib combination versus 3.1 months for ICT (HR: 0.42; 95% CI: 0.30, 0.59; p-value: <0.0001)Secondary endpoint of ORR by BICR was 37.1% for the darovasertib combination versus 5.8% for ICT (p-value: <0.0001), including 5 complete responses in the darovasertib combination armDarovasertib combination showed an early trend in improvement for OS versus ICTWell-tolerated, with manageable safety profile consistent with previously reported AEsNDA submission planned for H2'26 to support U.S. accelerated approval filing. Full data from OptimUM-02 to be presented at major

    4/13/26 6:00:00 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026

    SOUTH SAN FRANCISCO, Calif., April 10, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company, today announced plans to issue a joint IDEAYA and Servier pre-market press release and host a conference call and webcast on Monday, April 13, 2026 at 8:00 a.m. ET to disclose topline results from their ongoing Phase 2/3 registrational trial, OptimUM-02, evaluating darovasertib in combination with crizotinib in patients with first-line HLA*A2-negative metastatic uveal melanoma. The call will include members of IDEAYA's management joined by a distinguished key opinion leader.

    4/10/26 4:05:00 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZ
    $BENF
    $CLEU
    $DYNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Paramount Global

    SC 13D/A - Paramount Global (0000813828) (Subject)

    12/12/24 4:14:51 PM ET
    $PARAA
    Broadcasting
    Industrials

    Amendment: SEC Form SC 13D/A filed by Maxeon Solar Technologies Ltd.

    SC 13D/A - Maxeon Solar Technologies, Ltd. (0001796898) (Subject)

    11/26/24 8:54:35 PM ET
    $MAXN
    Semiconductors
    Technology

    Amendment: SEC Form SC 13D/A filed by R1 RCM Inc.

    SC 13D/A - R1 RCM Inc. /DE (0001910851) (Subject)

    11/22/24 4:06:56 PM ET
    $RCM
    Other Consumer Services
    Consumer Discretionary